Journal: Journal of the Endocrine Society
Article Title: Insulin receptor trafficking and interactions in muscle cells
doi: 10.1210/jendso/bvag020
Figure Lengend Snippet: Analysis of INSR tracks colocalized or not colocalized with CAV1 or CLTC. (A) INSR tracks that colocalized with CAV1 under 0 or 2 nM insulin (referred to as CAV1.Y.0nM or CAV1.Y.2nM below). (B) INSR tracks that colocalized with CLTC under 0 or 2 nM insulin (referred to as CLTC.Y.0nM or CLTC.Y.2nM below). (C) Diffusion coefficient (μm 2 /s) of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). The cumulative probability shows the distribution of the measurements, with the dots and numbers showing the median values (same for other cumulative probability plots). (D) Diffusion coefficient (μm 2 /s) of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (E) Track radius of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). (F) Track radius of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (G) Lifetime of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). (H) Lifetime of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (CAV1.N.0nM, n = 2 cells, 125 tracks; CAV1.N.2 nM, n = 2 cells, 96 tracks; CAV1.Y.0nM, n = 2 cells, 235 tracks; CAV1.Y.2nM, n = 2 cells, 228 tracks; CLTC.N.0nM, n = 4 cells, 597 tracks; CLTC.N.2nM, n = 2 cells, 91 tracks; CLTC.Y.0nM, n = 4 cells, 320 tracks; CLTC.Y.2nM, n = 2 cells, 55 tracks.) (2-ANOVA: # effect of colocalization, $ effect of insulin, % interaction of the 2 variables; Kolmogorov–Smirnov [KS] test: * P < .05, *** P < .0005.) Experiments shown were conducted in Ringer's buffer.
Article Snippet: INSR, CAV1, and CLTC were detected by the following Cell Signaling primary antibodies: INSRβ (1:1000, Mouse mAb, Cat. #3020S, RRID: AB_2249166), CLTC (1:1000, Rabbit mAb, Cat. #4796, RRID: AB_10828486), Caveolin-1 (1:1000, Rabbit mAb, Cat. #3267, RRID: AB_2275453), and HRP-conjugated VeriBlot secondary antibodies (1:200, anti-mouse Cat. #ab131368, RRID: AB_2895114; anti-rabbit ab131366, RRID: AB_2892718; Abcam) that do not bind to IgG heavy and light chains to reduce background noise.
Techniques: Diffusion-based Assay
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
![Analysis of INSR tracks colocalized or not colocalized with CAV1 or CLTC. (A) INSR tracks that colocalized with CAV1 under 0 or 2 nM insulin (referred to as CAV1.Y.0nM or CAV1.Y.2nM below). (B) INSR tracks that colocalized with CLTC under 0 or 2 nM insulin (referred to as CLTC.Y.0nM or CLTC.Y.2nM below). (C) Diffusion coefficient (μm 2 /s) of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). The cumulative probability shows the distribution of the measurements, with the dots and numbers showing the median values (same for other cumulative probability plots). (D) Diffusion coefficient (μm 2 /s) of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (E) Track radius of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). (F) Track radius of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (G) Lifetime of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). (H) Lifetime of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (CAV1.N.0nM, n = 2 cells, 125 tracks; CAV1.N.2 nM, n = 2 cells, 96 tracks; CAV1.Y.0nM, n = 2 cells, 235 tracks; CAV1.Y.2nM, n = 2 cells, 228 tracks; CLTC.N.0nM, n = 4 cells, 597 tracks; CLTC.N.2nM, n = 2 cells, 91 tracks; CLTC.Y.0nM, n = 4 cells, 320 tracks; CLTC.Y.2nM, n = 2 cells, 55 tracks.) (2-ANOVA: # effect of colocalization, $ effect of insulin, % interaction of the 2 variables; Kolmogorov–Smirnov [KS] test: * P < .05, *** P < .0005.) Experiments shown were conducted in Ringer's buffer.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3976/pmc12963976/pmc12963976__bvag020f7.jpg)
